The Business Magazine - Life Sciences - November 2024

NOVEMBER 2024

south east and oxfordshire

INSIDE:

LIFE SCIENCES SHOWCASE

IN ASSOCIATION WITH

THEBUSINESSMAGAZINE.CO.UK

1

2

THEBUSINESSMAGAZINE.CO.UK

LIFE SCIENCES SHOWCASE

THE OXFORDSHIRE REGION’S LIFE SCIENCES SECTOR FUELLING THE UK ECONOMY For the third year, we are delighted to collaborate on our life sciences supplement with leading national law firm Freeths and Milton Park, the 250-acre business and technology park

By Nicky Godding, Editor

Looking back over the last three years, it’s clear that the reputation of Oxfordshire’s life sciences sector continues to grow globally, and the University of Oxford is still spinning out more companies than any other UK university.

But complacency isn’t an option. The region must continuously promote the vibrancy of the sector, the opportunities available to those who want to bring their skills and build careers here, and the attractive lifestyle on offer when they move here.

With the change in government this summer has also come a new perspective on supporting the UK science sector.

Businesses in this country’s life sciences industry generated more than £108 billion in turnover in 2021-22, a 13 per cent increase from the previous year.

The new Labour government says it recognises the value of life sciences, and in February published its plan for the sector. This said that if Britain is to truly

lead the world, then we must back the industries in which we are already global leaders.

Life sciences is one of those and it has a huge role to play in Britain’s economic future.

A vibrant and supported life sciences sector will also help make the NHS fit for the future and pioneer breakthroughs which will transform and extend lives.

This is a positive intent which now needs to be supported with actions. In September Lord Darzi published his rapid investigation into the state of the NHS, commissioned by government.

The NHS surgeon and academic’s conclusions suggested there must be a tilt towards technology.

Lord Darzi said: “There is enormous potential in AI to transform care and for life sciences breakthroughs to create new treatments.” He also wants more support for British biopharmaceutical companies.

In August, the government gave a boost to those investing in life sciences, when it extended the Enterprise Investment Scheme and Venture Capital Trust. Both were set to end next April, but have now been extended 10 years to April 2035.

But more lab space is needed for start-ups, scale-ups and the big biotechs wanting to expand. More homes are also needed close to workplaces for those employed in the sector. Unless you support the industry holistically, it won’t thrive.

Our list of 100 life sciences businesses across the Oxfordshire region celebrates the diversity of innovation. Some companies are revenue-generating, others have that goal ahead of them.

Milton Park (the UK’s largest single ownership innovation community), and Freeths, voted UK law firm of the year in September, live and breathe the life sciences sector and understand better than most the challenges it faces, alongside the opportunities which they know are there for the taking.

THEBUSINESSMAGAZINE.CO.UK

3

LIFE SCIENCES SHOWCASE

OXFORDSHIRE: DRIVING THE UK’S LIFE SCIENCES SECTOR Claus Andersen and Philip Campbell

Supporting the region’s life sciences sector is a priority say the professionals During the years 2020 and 2021, investment into life sciences companies across the UK surged as investors poured money into Covid research over the course of the pandemic.

Inward investment into the sector in 2023 was £0.8 billion, a 21 per cent reduction compared to 2022. But we weren’t the only country to experience this. The USA and Ireland also saw reductions.

Many agree this was in large part thanks to investor optimism and expectation after the amazing vaccine achievements of Oxford University spin-out Vaccitech (now renamed Barinthus Biotherapeutic and listed in our 100 life sciences companies).

Equity finance raised by the UK life sciences sector similarly dropped last year.

But upwards trajectories can’t last forever and the investment market is now thought to be settling back down after a few years of exceptional volatility.

That has meant a drop in foreign direct investment into UK life sciences last year, the second year-on-year decline since 2021.

4

THEBUSINESSMAGAZINE.CO.UK

Last year equity finance fell to £2.9 billion, a 14 per cent decrease compared to 2022.

But again, similar decreases were seen in most comparitive countries.

Despite this, the UK was still ranked third in 2023, up from fourth the previous year and behind only the USA and China.

What can the government do to kickstart further growth in the UK’s life sciences sector?

It’s done two things already. In September it extended the Enterprise Investment Scheme (EIS) and the Venture Capital Trust (VCT).

Both were set to end next April, but this autumn the government announced it was extending them by 10 years to April 2035.

The schemes are designed to encourage investment into new or young companies through tax-relief incentives.

This boosts innovation, creating jobs and stimulating economic growth.

According to Philip Campbell, Commercial Director at Milton Park in Oxfordshire, the extension of the EIS and VCT is a great start – now the region needs to double down on creating the right conditions and support for investment.

LIFE SCIENCES SHOWCASE

Quite often a founder will see the science as the primary focus and building a business as secondary. The reality is that they need to do both

Aerial view of Milton Park

“For young companies it’s about getting going quickly,” he said. “At Milton Park we are very lucky that we have a simplified planning regime, strong infrastructure, excellent power provision and space for every size of company.”

Claus Andersen, Partner in law firm Freeths Life Sciences team, agreed. “Above all the government’s announcement on EIS and VCT has created some stability, and this is important. It takes a long time to get from idea to product commercialisation.

“But the government still has a big challenge ahead.

“While I understand the focus on closing the deficit, there is a difference between investing in growth and firefighting daily economic problems. The life sciences and technology sectors are two areas really driving the UK economy.”

Claus and Philip both pointed out that it was a pity that the government slipped out September’s EIS and VCT announcement without much fanfare.

Claus said: “It would have delivered a stronger message if a senior government minister had made the announcement, underlining its commitment to the sector.”

Philip added: “If the government doesn’t

make a noise that it is supporting companies investing in this country – that if they invest, they will be rewarded in tax reductions – money will go to other European countries, or to the USA.” To drive economic growth, the UK needs a fair tax regime for investors and stronger communication to ensure they understand the benefits.

Put your business head on But it’s not all about those with the money. If young companies want to attract investment, they need to think of themselves as businesses from the start, not simply researchers with a great idea.

“Start-ups and founders should take advice early,” said Claus. “They need to establish themselves as investible entities as soon as practical, because the earlier they can attract investment, the more opportunity they will have to develop their IP into a commercial business. Investors seldom commit to fund an unpatented idea – they need clarity on a business’s direction and ambition.

“Quite often a founder will see the science as the primary focus, and building a business as secondary. The reality is that

they need to do both.”

A start-up needs to decide what it wants to be, how long it will take to get there and how much investment is needed to make that happen.

Philip added: “By putting the start-up on a business footing early, the founder will reduce their cash burn, so it makes practical sense.

“From a real estate perspective, particularly with young companies, we are seeing growing demand for more fitted space, so that they don’t bear the capital cost of fit-out.”

The whole of Milton Park is under single ownership, in fact it is the largest single ownership innovation community in the UK. “That makes it a lot easier for us to help young companies size their lab and office space up or down as needed,” said Philip.

“We offer a ladder of growth. From a virtual offering where companies just have an address, to co-working and grow-on lab space, right up to companies such as Evotec and Adaptimmune which employ hundreds of people and have significant lab space at Milton Park.

THEBUSINESSMAGAZINE.CO.UK

5

LIFE SCIENCES SHOWCASE

We are all laying the foundations for future generation

Supporting the Oxford life sciences eco-system Oxford also has a strong business support system, from the county’s local enterprise partnership to Oxford University Innovation, the university’s technology transfer and consultancy company which manages the research and development of university spin-offs.

There is also Oxford Science Enterprises, the early-stage venture capital firm which invests in spin-outs, and Advanced Oxford which – through its membership of senior leaders from the area’s biggest knowledge-intensive businesses – supports the long-term development of the Oxford region. And there are many other similar support organisations.

Success doesn’t happen without strong advocacy and support. “It’s a great privilege to work within the life sciences ecosystem,” said Philip. “We are all laying the foundations for future generations.”

Claus added: “Working collectively also helps create fertile conditions for growth.”

Attracting life science skills to Oxfordshire But it’s no secret that certain skills are in short supply in the UK, as in many other European countries, and everyone is competing for talent.

What can be done to encourage more skilled people into the UK’s life science companies, particularly the Oxfordshire region?

6

THEBUSINESSMAGAZINE.CO.UK

Oxfordshire offers huge amounts of leisure activities to attract those relocating to the area. The Blenheim Palace triathlon, which attracts hundreds of participants, will take place on Saturday June 7 next year

Oxford has a strong global brand A renewed focus by government on housebuilding has been welcomed across the scientific community and its support ecosystem, but there’s much more to be done.

competitive and substantial life sciences cluster more widely, along with celebrating the benefits of the region as a great place for work and its leisure activities.

“Oxfordshire’s life sciences businesses need lab space and their staff need homes to live in,” said Claus. “We also need to develop home-grown talent and make it easier for those looking to build their careers in the UK to obtain skilled worker visas.”

“We need to share more broadly the high quality of life that people enjoy in the Oxfordshire region and beyond, and because we are part of the Oxford/ Cambridge Golden Triangle – the UK’s biggest scientific cluster, there are ample opportunities for skilled people to build their careers here,” Claus added.

Oxfordshire should promote its globally

LIFE SCIENCES SHOWCASE

Claus Andersen and Philip Campbell overlooking Milton Park

He added: “The UK has a very good reputation in many parts of the world, but we can’t be complacent. With so much global competition, we need to ensure that the positive aspects of living in the UK – our open and relatively peaceful democratic society, the opportunities waiting to be seized and our beautiful towns, cities and countryside are all fully appreciated and promoted.”

Philip added: “It used to be a no-brainer to set up a business in the UK. And it still is for many, but we know there is now tougher competition from other countries.”

However, in our list of 100 life sciences companies, it is evident that the UK is still a destination of choice for scientists and business founders from all over the globe.

Many of the companies selected for the list are led by scientists from across the world and this is a reason to be cheerful. The UK is still recognised as having one of the most fertile innovation economies in the world.

the world knows the strength of this region’s life sciences sector.

“We have the ideas and the opportunities,” said Philip. “We just need to ensure that we have the fuel (a strong economy and the right skills) to continue to power that engine of growth.”

The passion and optimism that runs through Oxfordshire’s life sciences community is clear to see when the

region’s scientific community comes together, which it does regularly at the many networking, conferences and other events held across the region.

“Oxfordshire is an exciting place to be,” said Philip. “Innovation is a team sport and we work hard to develop collaboration and partnerships to drive knowledge exchange and scientific excellence.”

Claus agrees. “Oxford has a strong global brand.

“Despite our determination not to be complacent and our acknowledgement that everyone needs to keep their feet on the accelerator, the world knows the strength of this region’s life sciences sector.

“And we, representing the professional sector, are supporting those with the ideas, technologies and scientific discoveries that could change and improve the world as we know it.”

THEBUSINESSMAGAZINE.CO.UK

7

LIFE SCIENCES SHOWCASE

100 of the region’s most innovative and ambitious life sciences companies Company name Founded

CEO

Description

Location

Akamis Bio

2006

Howard Davis

Clinical-stage oncology company leveraging its Tumor-Specific ImmunoGene Therapy platform to improve cancer outcomes

Abingdon Science Park

Alethiomics

2021

Prof Beth Psaila

Developing life-changing treatments for patients with blood cancer

Oxford

AlveoGene

2023

David Hipkiss, Executive Chair

Transforming rare respiratory disease outcomes using Inhaled gene therapy

Oxford

AMS Biotechnology (Europe)

1987

Alex Sim

Leading provider of quality life science research reagents and services

Milton Park, Oxfordshire

Accession Therapeutics

2020

Bent Jakobsen

With its stealth virus platform technology, Accession Therapeutics is focused on treating intractable and widespread forms of cancer

Oxford Business Park, Oxford

Active Needle Technology

2016

Ian Quirk

Precision needle targeting in ultrasound-guided interventional procedures, such as cancer biopsy, drug delivery and regional anaesthesia

Culham Science Centre, Abingdon

Adaptimmune Therapeutics

2014

Adrian Rawcliffe

Clinical-stage biopharmaceutical company developing novel cancer immunotherapy products for cancer patients

Milton Park, Oxfordshire

Adaptix

2009

Sarah Small

3D X-ray technology at point-of-use

Begbroke Science Park, Oxford

Arctoris

2016

Tom Fleming

Tech-enabled contract research organisation

Milton Park, Oxfordshire

Arcturis Data (UK)

2018

Alex Snow

Uses real-world data to support the discovery and development of new medicines

Oxford Technology Park, Kidlington

Avaxipen

2017

Robin Cohen

Developing needle-free solid dose vaccines

Milton Park, Oxfordshire

Barinthus Biotherapeutics (UK) (formerly Vaccitech)

2016

Bill Enright

Advancing the next generation of immunotherapies that lead T cells to gain Harwell Campus, control over disease Oxfordshire

Blue Earth Therapeutics

2021

David E Gauden

Clinical stage radiopharmaceutical company advancing next generation targeted radiotherapeutics to treat cancer patients

Brainomix

2010

Dr Michalis Papadakis Creates AI-powered imaging biomarkers enabling precision medicine

Oxford

BV Biomedical

2020

Roy Garvin

Developing a novel treatment for multiple sclerosis

Oxford Science Park, Oxford

Coding Bio

2020

Simon Bornschein

Building immunotherapies for cancer patients by testing millions of candidates to find the best therapies

Headington, Oxford

Convatec

1977

Karim Bitar

Advanced wound care, ostomy, continence and infusion care

Milton Park, Oxfordshire

Dark Blue Therapeutics

2020

Alastair Mackinnon

Drug discovery company leveraging therapeutic and disease insights to exploit cancer’s vulnerabilities and dependencies

Oxford Science Park, Oxford

Diffblue

2016

Toffer Winslow

Using AI technology to fundamentally transform the way developers write code

Oxford

DJS Antibodies

2014

Dale Starkie, Director Scientist

Developing a new platform for antibody discovery to create novel therapeutics

Oxford

Eden Research

1995

Sean Smith

Developing sustainable biopesticides and plastic-free encapsulation for global crop protection

Milton Park, Oxfordshire

Oxford Expression Technologies Ltd

2006

Dr Adam Chambers, Principal Scientist

Centre of Excellence in the application and development of baculovirus science

Oxford

Oxford Gene Technology Ltd

1999

Adrian Smith

Pioneer in hybridisation technology and a leading provider of clinical research and diagnostic solutions

Kidlington

Oxford Genetics Ltd 2011 (OXGENE)

Weimin Valenti (General Manager)

Helps pioneering companies accelerate the discovery and biomanufacture of their CAR-T/cell therapies and gene therapies

Oxford

Oxford Immune Algorithmics Ltd

Dr Hector Zenil, Owner

Deep-tech that applies predictive and generative Artificial General Intelligence (AGI) to deliver decentralised precision health and predictive medicine

Reading

2018

Oxford Science Park, Oxford

The Business Magazine has endeavoured to correctly describe the work of each life sciences company listed. However, the magazine does not accept liability for any inadvertant mis-representation.

8

THEBUSINESSMAGAZINE.CO.UK

LIFE SCIENCES SHOWCASE Company name Founded

CEO

Description

Location

Emergex Vaccines

2020

Professor Thomas Rademacher

Developing T cell-priming immune set-point candidates against viral and bacterial infectious diseases, using purely synthetic non-biological components

Milton Park, Oxfordshire

Enara Bio

2016

Kevin Pojasek

Exploring the hidden depths of cancer and T-cell biology to discover and characterise dark antigens, a novel class of shared immunotherapy targets

Oxford Science Park, Oxford

Etcembly

2019

Michelle Teng

Building the world’s largest machine learning database and immunology expertise to deliver powerful TCR immunotherapies through rapid computerassisted engineering

Harwell Campus, Oxfordshire

Evariste

2017

Anna Hercot

Developing small molecule therapeutics targeting synthetic lethal pathways in oncology

Oxford

Everest Biotech

1999

David Smoller

Specialists in anti-peptide and antigen affinity purified goat polyclonal antibodies

Upper Heyford

Evotec (UK)

1991

Dr Christian Wojczewski

Drug discovery, development and manufacturing

Milton Park, Oxfordshire

Evox Therapeutics

2016

Dr Per Lundin

Improving the natural delivery capabilities of exosomes, and developing a new class of therapeutics

Oxford Science Park, Oxford

Exscientia

2012

Dave Hallett

The first company to automate drug design and the first to have an AIdesigned molecule enter clinical trials

Oxford Science Park, Oxford

Flexsr

2023

Professor Aditi Lahiri

Developing more flexible speech recognition

Oxford

Fluorok

2022

Gabriele Pupo

Aiming to revolutionise the way fluorochemicals are produced worldwide

Oxford Science Park, Oxford

Gardin Agritech

2020

Sumanta Talukdar

Innovative optical sensor technology which can measure the health of crops, fruit and vegetables.

Milton Park, Oxfordshire

GeneOmics Solutions

2018

Prathiba Kurupati

Early diagnosis and treatment in a personalised fashion using multi-omics data

Oxford

GFC Diagnostics

2007

Dr Graham Cope

Specialists in point of care detection of smoking and cotinine measurements and treatment adherence in TB

Chipping Warden

Greywolf Therapeutics

2017

Peter Joyce

Addressing immune dysfunction in oncology and autoimmunity

Milton Park, Oxfordshire

Human Centric Drug Discovery

2021

James Peach

Improving neurology drug discovery by bringing more human data to the process

Oxford Centre for Innovation, Oxford

Hypha Discovery

2004

Liam Evans

Specialising in the synthesis, purification and characterisation of drug and agrochemical metabolites, API degradates and natural products

Milton Park, Oxfordshire

Immunocore

2007

Bahija Jallal

Commercial-stage biotechnology company that discovered, developed and commercialised the world’s first approved T cell receptor therapy

Milton Park, Oxfordshire

IngenOx (previously Celleron Therapeutics)

2022

Professor Nick La Thangue

The discovery and clinical development of new and innovative therapies to treat cancer

Oxford Science Park, Oxford

Iotasciences

2016

Dr Michael Lutz

Developing single-cell biology handling solutions

Begbroke Science Park, Oxford

Iuvantium

2022

Björn Schimmöller

Deeptech synthetic immunobiology company

Oxford

Ivy Farm Technologies

2019

Richard Dillon

Sustainable meat production

Oxford Business Park, Oxford

Life Research Oxford

2024

John Jain

Bringing together US and UK researchers in reproductive medicine to develop assays for studying and validating epigenetic modifications in human sperm DNA

Oxford Science Park, Oxford

MatchBio

2023

Omer Dushek

Improving functionality of Chimeric Antigen Receptor-based therapeutics using their proprietary range of bespoke synthetic receptors

Oxford

Mitorx Therapeutics 2021

Jon Rees

Reversing mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration

Oxford Business Park, Oxford

Nanolyse Technologies

2020

Imad Ahmed

Developing advanced materials with transformative applications and creating Harwell Campus, next-generation, nano-enabled chemical sensors Oxfordshire

Nanovation Therapeutics UK

2021

Dominik Witzgmann

Developing safe and efficient delivery of genetic medicines to target tissues in the body

Harwell Campus, Oxfordshire

THEBUSINESSMAGAZINE.CO.UK

9

LIFE SCIENCES SHOWCASE

Company name Founded

CEO

Description

Location

NeoVac

2021

Eran Eilat

Clinical stage company with an unique IP for lipid nanoparticles

Milton Park, Oxfordshire

Neuro-Bio

2013

Baroness Susan Greenfield

Using a new discovery to develop drugs to treat Alzheimer’s Disease

Culham Science Centre, Abingdon

Neu Health

2023

Caroline Cake

Making the latest Parkinson's disease and dementia care accessible for all

Oxford Milton Park, Oxfordshire

New England Biolabs

2011

Donald Comb

Leader in the discovery and production of enzymes for molecular biology applications

Niox Healthcare

1998

Ian Johnson (Executive Chairman)

Design, development and commercialisation of medical devices for asthma Oxford Science diagnosis and management Park, Oxford

Novo Nordisk Research Centre Oxford

2014

Dr. Bill Haynes (site head)

Novo Nordisk Research Centre Oxford focuses on identifying novel therapies for patients with type 2 diabetes and cardiometabolic diseases

Headington, Oxford

Nucleome Therapeutics

2019

Dr Mark Bodmer

Discover and validate first-in-class targets through genetics in the dark genome

Oxford Science Park, Oxford

Ochre Bio

2019

Jack O'Meara

Developing therapies for the biggest liver health challenges, from increasing donor liver supply to reducing cirrhosis complications

Oxford Science Park, Oxford

Ojas Immune

2024

Dr Aroul Selvam Ramadass

Identifying new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry

Oxford

Omass Therapeutics

2016

Ros Deegan

Identifying new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry

Oxford Business Park, Oxford

Optellum

2015

Johnathan Watkins

Developing Virtual Nodule Clinic, the first AI clinical decision support software for lung cancer management

Oxford Centre for Innovation, Oxford

Orbit Discovery

2020

Neil Butt

Developing technologies to significantly improve the throughput for screening biological molecules for affinity and function

Oxford Science Park, Oxford

OrganOx

2008

Craig Marshall

OrganOx’s Metra harnesses patented normothermic machine perfusion technology to preserve donor livers for up to 24 hours prior to transplant

Oxford Business Park, Oxford

Osler Diagnostics

2016

Connor Campbell

Developing and commercialising a portable lab to provide lab-quality diagnostics to anyone, anywhere, at any time

Oxford

Oxccu Tech

2021

Andrew Symes

Transforming CO2 into sustainable aviation fuel, chemicals and plastics

Oxford Oxford Science Park, Oxford

Oxehealth

2012

Todd Haedrich

Vision-based patient monitoring. Created the first digital observation tool for mental health

Oxford Biodynamics

2007

Jon Burrows

Developing and commercialising precision medicine tests for life-changing diseases.

Oxford

Oxford Biolabs

2009

Dr Thomas Whitfield

Developing solutions for unwanted signs of ageing, including hair loss, premature greying and skin ageing using naturally-based ingredients

Oxford Business Park, Oxford

Oxford Biomedica

1996

Dr Frank Mathias

Collaborating with innovative pharmaceutical and biotechnology companies to make cell and gene therapy a universally accessible clinical option

Oxford

Oxford Biotherapeutics

2003

Christian Rohlff

Clinical stage oncology company focused only on first-in-class immune therapies, with special emphasis on improving outcomes for patients with solid tumors who respond poorly to PD-1 inhibitors

Oxford Science Park, Oxford

Oxford Brain Diagnostics

2018

Dr Steven Chance

Pioneering approach to analysing the brain's cellular structure to support drug development in defeating Alzheimer's and other neurodegenerative conditions

Oxford Centre for Innovation, Oxford

Oxford Cancer Analytics

2020

Dr Peter Jianrui Liu

Enabling curative cancer treatment through early detection

Oxford

Oxford Cannabinoid Technologies

2017

Clarissa SoweminoCoker

Developing non-addictive pain medications to reduce the reliance on opioids

Oxford

Oxford Drug Design 2001

Dr Alan D Roth

Leveraging knowledge of tRNA synthetases and generative AI methods to rapidly advance multiple drug candidates to the clinic

Oxford Centre For Innovation, Oxford

Oxford Endovascular

2015

Mike Karim

Developing next-generation medical devices for neurovascular disease

Oxford Business Park, Oxford

Oxford Nanopore Technologies

2005

Dr Gordon Sanghera

Makes a novel generation of DNA/RNA sequencing technology that provides rich data which is fast, accessible and easy to use

Oxford Science Park, Oxford

10

THEBUSINESSMAGAZINE.CO.UK

LIFE SCIENCES SHOWCASE

Company name Founded

CEO

Description

Location

Oxford Optical Laboratories

2023

Rob Stevens

Innovating to address emergent problems in optical systems for human and machine vision

Witney

Oxford Vacmedix UK

2012

William Finch

Developing therapeutic agents for the treatment of cancer

Oxford Science Park, Oxford

Oxgene

2009

Keith Meaney, General Manager

Helps accelerate the discovery and biomanufacture of their CAR-T /cell therapies and gene therapies

Oxford Science Park, Oxford

Oxitec

2002

Grey Frandsen

Leading developer of biological solutions to control pests that transmit disease, destroy crops and harm livestock

Milton Park, Oxfordshire

Oxsonics

2013

Jérôme Marzinski

Clinical-stage therapeutics company developing a platform technology to make anti-cancer drugs smarter

Oxford Science Park, Oxford

Oxular

2014

Mark Gaffney

Providing innovative approaches and treatment options to retinal specialists

Oxford Science Park, Oxford

Pathios Therapeutics

2017

Paul Higham

Clinical-stage oncology and immunology company

Milton Park, Oxfordshire

Perspectum

2012

Rajarshi Banerjee

Advanced imaging solutions that can help doctors make better decisions, personalise care for patients and ensure better outcomes

Oxford Business Park, Oxford

Physiomics

2001

Dr Peter Sargent

Transforming oncology drug development

Milton Park, Oxfordshire

Precision Life

2013

Dr Steve Gardner

Precision medicine company aiming to identify, target and treat the biological mechanisms driving disease within subgroups of patients

Long Hanborough, Oxford

Quantum Dice

2020

Dr Ramy Shelbaya

Harnessing the fundamental quantum properties of light to enable secure encryption

Oxford

Replimune

2015

Sushil Patel

Developing cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response

Milton Park, Oxfordshire

River Therapeutics

2022

Paul Brennan

Drug discovery company dedicated to the development of novel therapeutics for the treatment of diseases with significant unmet clinical need

Oxford

Samsara Therapeutics

2019

Meenu Chhabra Karson (executive chair)

Treating neurodegenerative disease by restoring autophagy

Wood Centre For Innovation, Oxford

Serenox

2022

William Mawalla

Established to deliver rapid and accurate diagnostics to sub-Saharan populations via the set up of local DNA sequencing capacity

Chalgrove, Oxfordshire

Sibelius Natural Products

2009

Peter Leyland

Supporting healthy ageing with its portfolio of natural ingredients to meet increasing market demand

Milton Park, Oxfordshire

Spybiotech

2017

Mark Leuchtenberger

Developing a new generation of vaccines

Oxford Business Park, Oxford

Summit Therapeutics

2003

Bob Duggan

Biopharmaceutical oncology company

Milton Park, Oxfordshire

SynaptixBio

2021

Dan Williams

Enabling the translation of ground-breaking research in TUBB4a Leukodystrophy into a transformative therapy

Oxford Business Park, Oxford

Synox Therapeutics UK

2021

Ray Barlow

Aiming to establish emactuzumab as a best-in-class drug to address the unmet needs of patients

Oxford Science Park, Oxford

Synthlab

2023

Priyansh Gujarati

Predicting chemical reaction success using neural networks and experimental datasets

Oxford

The Electrospinning 2008 Company

Ann Kramer

The design, development and manufacturing of biomaterials, translating innovations from concept to clinic

Harwell Campus, Oxfordshire

Theolytics

2017

Margaret Duffy

Discovery platforms harness the power of viruses to systematically identify therapies optimised for a chosen patient population

Oxford Science Park, Oxford

Ultromics

2017

Dr Ross Upton

Detection and phenotyping of heart failure through AI

Oxford Business Park, Oxford

Vertex Pharmaceuticals

1994

Reshma Kewalramani

Focus on discovering, developing and producing innovative medecines for Milton Park, serious diseases Oxfordshire

Verso Biosense

2009

Nadia Whittley

Developed a micro-sensing device that could revolutionise fertility treatment

Milton Park, Oxfordshire

Wild Bioscience

2021

Ross Hendron

Designing crops to be more sustainable. Building a platform to develop solutions for next generation crops

Milton Park, Oxfordshire

THEBUSINESSMAGAZINE.CO.UK

11

LIFE SCIENCES SHOWCASE Gardin – protecting under cover crops

Growing

business makes our food chain more resilient and tastier

12

THEBUSINESSMAGAZINE.CO.UK

LIFE SCIENCES SHOWCASE

Serial entrepreneur Sumanta Talukdar has turned his attention to improving food quality

By Nicky Godding, Editor Three years ago, Sumanta Talukdar sold the business he co-founded in 2014 to the owner of Snapchat for a cool $500 million.

“They measured everything else: the air, soil, temperature, sunlight and how much fertiliser they used – everything in fact but the product itself.

Their company, WaveOptics, had developed the technology behind augmented reality displays which Snapchat’s parent company, Snap Inc, aims to deploy in spectacles.

“And I thought, wow. Every industry I’ve ever worked in has an insane focus on measuring the product.

And you’re not.”

After a decade of hard graft proving the technology, securing funding and building the business you’d have thought he’d want to take a breather.

But that’s not how Sumanta, 46, rolls. In 2019 he launched another business which now has his full attention. Why do it all over again?

“Because I can’t imagine doing anything else,” he says.

His latest venture is Gardin. The company has developed innovative optical sensor technology which can measure the health of crops, fruit and vegetables.

Alongside is a suite of machine learning analytics to help increase crop yields, decrease their variations, improve forecasting and reduce the resources used while the crop is growing. Why turn his attention to agri-tech and digital phenotyping from augmented reality?

“I began to ask myself why some food looked great but tasted terrible, and wondered how did such food make it all the way through the supply chain to me?

Food supply chains are in trouble “We all know that food supply chains are in trouble and climate change is causing havoc, and I thought very smart people would be working on solving the problem. Then I got more curious and started talking to the industry, and realised I was wrong. People were not asking the questions that I was to solve these problems.

“When I talked to crop growers, and others right through the supply chain, I discovered they weren’t measuring their product.”

“I’ve worked in many industries, but this time I felt there was an opportunity to develop something which will have more of an impact.”

The idea for Gardin is planted Sumanta started by looking at what needed to be measured, because that would lead to effective decision-making. “The only metric that the food industry has been using for generations is tonnage,” he said. “The farmers invest in what they think are the right conditions to grow their crops, but don’t analyse the crop itself, except what it looks like, and that isn’t evident until later.

“I remember thinking it’s a bit like BMW checking to see if the engine turns over smoothly, after doing the paint job. Why wait until the product is almost ready when it’s too late to do something about it?”

Armed with these questions and some early research, Sumanta went to the industry. “I asked them, ‘If I could tell you what’s happening with your crops as they grow, not when they’ve almost grown, would you be interested? And what normally takes weeks and months to learn could be identified in less than 12 hours.’”

The farmers and growers he spoke to began listing all the ways they could use the technology in reducing costs and risks – and increasing productivity.

Having identified the need and undertaken extensive due diligence (which took around two years), he knew that if the problem could be solved, it could help combat a major and growing world problem: food shortages.

THEBUSINESSMAGAZINE.CO.UK

13

LIFE SCIENCES SHOWCASE

Just four years from seed funding to commercialisation By 2020 he was building his team and the following January he’d raised $1.3 million in pre-seed funding. By December 2021, he’d secured a further $10.8 million for the business, which by now had moved to lab space at Milton Park in Oxfordshire.

It took just two years for the company to develop the technology, secure accreditations and begin shipping the product.

What has been the hardest part of the Gardin project? “Developing the product of course,” says Sumanta, “But also understanding the pricing structure in agriculture, which is different.

“In most industries, you develop a product that solves the problem and price it accordingly. But growers are some of the most time-pressured people in the

world. They don’t have time to faff around with the prototypes and discuss pricing strategies. The product has got to work and deliver value, otherwise they will be stuck with produce they can’t sell.

A generational shift for farmers and growers “Since the dawn of agriculture growers have done what their forefathers have done. And that was fine for generations.

But climate change means seasons are now unpredictable, energy prices are soaring and farmers are faced with major decisions such as how much expensive fertiliser to buy and how much irrigation is needed. You can put moisture sensors in the soil but that’s not actually measuring what the plant is using. Our product can tell us if the plant needs more water or less, or of it needs more light, or minerals in the soil or if the temperature isn’t right. And we have that insight, not by guesswork but by proper analysis of the crop.”

Up until 15 or so years ago, our solution wasn’t needed because the climate wasn’t as unstable as it is now

Why haven’t other companies developed such a product sooner? It all comes down to timing says Sumanta.

“Up until 15 or so years ago, our solution wasn’t needed because the climate wasn’t as unstable as it is now. And because Covid revealed the fragility of the food supply chain, we were able to secure funding to invest in the research and development.”

Gardin - growing lettuces under cover

14

THEBUSINESSMAGAZINE.CO.UK

LIFE SCIENCES SHOWCASE

Covid and other recent natural disasters (such as the California wildfires and widespread flooding globally) have revealed an inconvenient truth: many countries rely too much on imported food.

If their supply chain stops, some have only days of food supply for their population.

Early adopts of Gardin technology see major results Early adopters of Gardin’s technology are growers, specifically those growing anything undercover: what’s called protected cropping.

That spans produce grown in high-tech glass greenhouses or under the millions of hectares of polytunnels in countries such as Spain and Italy.

“We want to focus on that segment for the next two to three years and become dominant in protective cropping in the Western Hemisphere,” Sumanta explained.

Gardin is also working with global agriculture companies such as Syngenta and Bayer.

Transparency is also very important. We don’t promise what we can’t deliver

“I learned from my previous life that once you prove that something thought really difficult is possible, mental barriers drop for competitors, so we had to move fast,” he added.

“And we had to find brilliant people who are fantastic at the things I can’t do well and give them well defined and clear

ownership of what they’re doing so they can just get on with it. Transparency is also very important. Not just internally but with our customers. We don’t promise what we can’t deliver.”

So everything is rosy in Gardin? It’s still early days, but the technology has already been recognised as a game-changer.

Any company that has fresh produce as part of its supply chain is going to see the benefit, from the global agri-techs to retailers such as Walmart, Mars and others.

Sumanta said: “These companies are making decisions on fresh produce many times a day. Getting them wrong costs them and their suppliers a lot of money.

We have proved that we can help them make better decisions.

“Recently a European customer said that it had achieved a five per cent increase in productivity. The company is getting higher yields and using less energy and less light, and that’s deeply satisfying.”

THEBUSINESSMAGAZINE.CO.UK

15

LIFE SCIENCES SHOWCASE

WHAT DOES IT TAKE TO BE A SUCCESSFUL UNIVERSITY SPIN-OUT? It takes a brilliant idea along with the time, money, resources and patience to successfully spin it out – and a fair amount of luck

Oxford Science Enterprises is based in Woodstock Road, Oxford

Over the past two decades, UK universities have increasingly invested in supporting the growth of their local spin-out ecosystems.

This has been encouraged by government through the Higher Education Innovation Fund in England, and universities are increasingly being assessed on their commercialisation performance.

But according to the latest Spotlight on Spin-outs 2024 from Beauhurst, commissioned by The Royal Academy of Engineering and published in April, investment in spin-outs declined significantly in 2023.

The total value of equity investment in UK spin-outs fell by a more than 30 per cent between 2022 and 2023, from

16

THEBUSINESSMAGAZINE.CO.UK

£2.66 billion to £1.66 billion. Mean deal sizes fell from £5.7 million to £4.32 million.

Why is this? Perhaps it’s because the juggernaut of enthusiasm and belief in life sciences seen during Covid has dropped down a few gears.

Remember Oxford University’s spin-out Vaccitech? (now renamed Barinthus Biotherapeutics and listed in our 100 top life sciences companies). It spun out of the university in 2016 with seed funding of £10 million.

That early investment allowed it to develop its vaccine platform so that when the world came calling, it was ready to save millions of lives during the pandemic.

There’s nothing like hope and expectation

to drive investment and a lot of money headed to young promising spin-outs in the following months. But as the pandemic (thankfully) receded, investment has pivoted to safer asset classes.

The reduced appetite for risk has also not been helped by the uncertain economic outlook last year, when the UK was faced with the threat of recession.

Last November, the government published an independent review of university spinout companies.

It said that world-class centres of spin-outs need the right mixture of a diverse and experienced pool of academic founders creating intellectual property (IP) and working closely with experienced start-up operators.

LIFE SCIENCES SHOWCASE It also needs anchor institutions, particularly universities, to nurture scientists and researchers to generate worldleading IP in science and technology and supporting a connected local ecosystem so that knowledge can be shared.

Funding has always been an issue for spinout companies. The report recommends that the government should increase funding for proof-of-concept work to develop confidence in an idea or product before it’s spun out.

And don’t forget the professional support needed – the IP attorneys, law firms, investors, fund-raising experts and financial advisers who will work with a researcher – whose deep scientific knowledge and experience may not necessarily be matched by commercial savvy.

And researchers and founders need easier access to expert advice, along with entrepreneurship and commercialisation training.

Oxford-CambridgeLondon “Golden Triangle” leads the UK The government report acknowledges that there are very few places in the world where all these capabilities are working as they should. In the USA it’s The Bay Area, Boston and San Diego. In the UK, the Oxford-Cambridge-London “Golden Triangle” leads the way by a fair distance, although other regions around Bristol and Bath are growing fast, as is Birmingham, where a new health innovation campus aims to establish the Midlands as a leading life sciences research and development hub. But that all takes time.

The review puts forward a number of recommendations to accelerate the UK towards a bigger, more effective spin-out ecosystem which it says will help grow the economy, attract more talent and turn the UK into a science and technology superpower that successive governments have dreamed of for years.

These include founders and their universities agreeing market terms on spin-out deals (spin-out deal terms agreed between founders, investors, and universities have long been a topic of hot debate, with some universities taking 20 per cent of equity in a spin-out, or even more).

Other recommendations include the setting up of a national register of spinouts, and universities publishing more information about their typical deal terms.

The University of Oxford is the UK’s leading university for spin-outs. Since 2011 it has spun out 210 companies. The University of Cambridge comes second, with 149 spin-outs in the same period.

Other universities in the region spinning out companies include the University of Southampton, with 42 spin-outs, The University of Surrey, 20 and The University of Sussex, 11, according to the Beauhurst/ Royal Academy of Engineering report.

Jim Wilkinson is Chief Financial Officer at Oxford Science Enterprise (OSE), which helps researchers and scientists translate their ideas into successful businesses. It helps young companies attract the right talent and personnel, connects it with potential investors and helps with the development of a PR strategy to get the right message across.

OSE launched in 2015 when it raised £600 million (and in fact led the Vaccitech seed funding round of £10 million the following year). It invests in companies that are part of the Oxford cluster (including those based on the city’s science parks and at the Saïd Business School).

To date OSE has invested in more than 100 equity deals in spin-outs, valued at more than £1.45 billion and has brought in more than 200 investors.

Jim Wilkinson, Chief Financial Officer at Oxford Science Enterprise (OSE)

companies and pension funds to family offices and high net worth individuals.

“We predict that there will be £5 billion per year being invested in Oxford spin-outs by 2035, but we cannot be complacent.

Getting IP out into the world is incredibly important and has a massive impact on improving world health. It also creates a stream of commercial income for both founder and the university, which can then be invested back into the ecosystem.

“We spend a lot of our time inviting investors in, introducing them to the companies so they can choose what they want to invest in, because if we match the right companies with the right investors, they have a much better chance of success.”

Oxford Science Enterprises will also help the founder pick a management team to drive the company.

“Getting IP out into the world is our priority”

“That management team will generally consist of someone who’s either familiar with the spin-out system and has done it before, or a PhD student who understands the science and puts them with an experienced chair and board to support them,” explained Jim.

Jim said: “We look at potentially worldleading life science discoveries in all sorts of areas, from drug development to quantum computing and we now have all sorts of investors on board, from

“Sometimes that student develops their commercial skills to such an extent that they can effectively lead the company, or they may prefer to transition their role to become chief scientific or technical officer.”

THEBUSINESSMAGAZINE.CO.UK

17

LIFE SCIENCES SHOWCASE Biotech lab

Hot investments What’s hot to invest in? Artificial Intelligence, telecoms, engineering biology, semi-conductors and quantum computing, according to the Beauhurst report.

“We have been investing in quantum computing for quite a few years. And in the early days it was tough to attract investors,” said Jim. “There were a lot of discussions within our investment committee. They said things like: “so no-one knows what it’s going to cost, how long it’s going to take to commercialise, what the market is or even the product the spin-out is going to launch, and you still want us to invest?

18

THEBUSINESSMAGAZINE.CO.UK

“But we knew it was the future, so we invested in four quantum companies and last year we attracted more investment in quantum than in any other area.”

Jim says the same thing happened with Vaccitech. “Investment in vaccines weren’t exciting – but then they were, because of Covid. And now the company, as Barinthus Biotherapeutics, is continuing to extend its work.”

Barinthus is now quoted on the NASDAQ exchange in the USA, as is Pepgen, another University of Oxford biotech spinout. The university retains a percentage of the intellectual property in both companies.

Keeping it in the Oxford community It’s important to OSE that as many of the companies as possible which spin out of the university stay in the Oxfordshire area.

“Out of the 126 companies we have supported, around seven are in London and seven are in the USA but the rest, more than 80 per cent of them, are still in Oxford and that’s important because it helps retain the ecosystem,” said Jim. “In 2022, £2.9 billion was invested in UK university spin-outs and half of that came to Oxford. But we need more UK universities to support their spin-out

LIFE SCIENCES SHOWCASE ecosystems, as Cambridge does alongside us.”

The bigger the UK’s life sciences sector, the more it will attract investors from all over the world.

Out of the 126 companies we have supported, around seven are in London and seven are in the USA but the rest, more than 80 per cent of them, are still in Oxford

“Oxford is fortunate that we have the knowledge to lead the way and we’re still evolving,” said Jim. “There are so many academics at Oxford working on the most amazing ideas, we’ve hardly scratched the surface of the potential here.”

It can take up to a year from meeting a scientist or researcher in an Oxford University lab and identifying the IP, to spinning out a company, but that’s quicker than it used to be, and OSE and investors expect to support a spin-out for between 10-14 years.

“OSE is now nine years old and we haven’t sold many companies yet because they’re not mature enough,” said Jim. “But in 2026 or 2027 we do expect some of those companies to sell.

“Shareholders will reinvest some of that money, and those who have made money from the company itself are also very likely to invest. That’s when the Oxford ecosystem will really start to look like Boston in the USA.”

TOP 20 Academic Institutions by total number of spin-outs tracked since 2011 to January 2024 UNIVERSITY OF OXFORD

210

UNIVERSITY OF CAMBRIDGE

149

IMPERIAL COLLEGE, LONDON

124

UNIVERSITY COLLEGE, LONDON 93 UNIVERSITY OF MANCHESTER

86

UNIVERSITY OF BRISTOL

76

ROYAL COLLEGE OF ART

72

UNIVERSITY OF EDINBURGH

66

SWANSEA UNIVERSITY

57

QUEEN’S UNIVERSITY, BELFAST 56 UNIVERSITY OF STRATHCLYDE

48

UNIVERSITY OF WARWICK

47

FALMOUTH UNIVERSITY

46

UNIVERSITY OF SHEFFIELD

45

UNIVERSITY OF SOUTHAMPTON 42

The Wood Centre for Innovation, which opened in 2019, is now one of Oxford’s leading start-up communities. It is part of Headington’s Science Cluster

Spin-out: A start-up company which has been created based on intellectual property generated through a university’s research

UNIVERSITY OF NOTTINGHAM

39

UNIVERSITY OF LEEDS

38

UNIVERSITY OF GLASGOW

38

NEWCASTLE UNIVERSITY

38

UNIVERSITY OF BIRMINGHAM

34

Source: Beauhurst/Royal Academy of Engineering

THEBUSINESSMAGAZINE.CO.UK

19

LIFE SCIENCES SHOWCASE

ANGELS WATCH OVER THE START-UP SECTOR It’s tough being a start-up: You’re too small to attract private equity or venture capital, but you won’t survive without financial backing.

Could an angel investor be the answer?

By Nicky Godding, Editor Government support for start-ups is in short supply, so where does a very young company find the investment to get established?

Private equity and venture capital companies are seldom interested in a young business until it’s got something to show, and it can be awkward asking friends and family to invest when you can’t promise they’ll get their money back quickly (if at all).

Angel investors can be one answer for fledgling life sciences companies.

But Jens Tholstrup, executive chairman of Oxford Investment Opportunity Network (OION), points out that even securing angel investment is tough.

OION is one of the UK’s oldest and most active business angel networks. Established in 1994 it links founders with investors at regular showcase events.

A report published in September by active investor Parkwalk and data analysis company Beauhurst, revealed that first time funding has been trending down, with almost half the number of deals completed last year on 2021 levels (120) - highlighting a potential bottleneck in early-stage funding.

20

THEBUSINESSMAGAZINE.CO.UK

Jens Tholstrup, executive chairman of Oxford Investment Opportunity Network (OION)

It’s often said that Britain is good at start-ups but less good at scale-ups. As a result, the government provides more direct support to scale-ups – but to Jens, that’s the wrong way round.

“If a founder doesn’t get off to a good financial start, they’ll spend a lot of time trying to fundraise, and not enough focusing on the business itself. And as soon as they’ve raised seed investment, they have to start fund-raising for the next round.”

But there is one scheme that has proved its worth for both investors and start-ups over the last 30 years, and which the government has now extended for a further decade.

The Enterprise Investment Scheme (EIS) is aimed at stimulating investment in earlystage businesses by providing attractive tax reliefs to those investing.

“In angel investment networks, finance is secured from high-net-worth individuals who benefit from the EIS scheme,” explains Jens.

This works for both investor and investee.

The investor gets generous tax relief, and a young business secures funding and at the

same time benefits from the involvement of highly experienced businesspeople who are ready and more than willing to offer support and advice.

OION has around 500 investors across its network from all backgrounds and sectors.

But with the new government issuing dire warnings on the state of the UK economy, the risk climate for investors is more challenging than it was.

While the 10-year extension of the EIS scheme is welcome, investors are wary of other potential tax rises. This magazine will be published before the Autumn budget, but it’s inevitable that the tax burden will increase.

A community of investors can deliver better results According to Jens, the value of the EIS is often under appreciated. “The proportion of higher rate UK taxpayers taking advantage of the EIS scheme is low. More could be done to promote it, especially as it’s now been given a further 10 years of life.”

Angel investors seldom invest in a company

LIFE SCIENCES SHOWCASE alone. And it’s increasingly important to them who they invest alongside.

“They also want to know how much early investment is required, when follow-on funding is likely to be needed and whether additional management expertise should be brought in,” said Jens.

“A group of investors will work together in the interests of the start-up’s future, especially if they’re in it for the long-term.

“Angels investing in life sciences understand the often long regulatory pathways to commercialisation.”

But there is good news for young companies. The Parkwalk/Beauhurst report reveals that UK spin-out investment is showing signs of recovery following a challenging year in 2023.

In the first six months of 2024, spin-outs secured more than £1 billion in funding. If this trajectory continues for the rest of the year, investment for the year could surpass 2023 levels, signalling a resurgence for the UK’s most innovative companies.

While first-time funding has trended down, the report does suggest that a culture of commercialisation with successful Technology Transfer Offices has been established across the UK’s university base.

Annual spin-out investment has quadrupled in 10 years rising from £514 million (2014) to an estimated £2.3 billion in 2024.

Jens is also encouraged by the flow of new spin-outs.

In the first six months of this year, the top UK university for spin-outs was, again, the University of Oxford, with 62 companies.

The University of Cambridge and Imperial College London had 45 and 28 respectively, followed by the University of Bristol, with 26.

Other universities from across the region appearing in the list include the University of Southampton, which spun out 14 companies and the University of Warwick

As long as we continue to see a continued strong flow of interesting new businesses, then there will be a wide range of opportunities for our angel investors

which spun out 10. The University of Surrey spun out five.

Angels are thinking more with their heads than their hearts, according to Jens, and that’s good for both parties.

“If they’ve done it before, they’ll know the issues.

“They will be looking for a good exit, but any gains they make they’re often willing to put back into the market. So the underlying dynamics for the sector are strong.

“As long as we continue to see a strong flow of interesting new businesses, then there will be a wide range of opportunities for our angel investors.”

Oxford is a very vibrant eco-system Most of OION’s investors are based in the UK, because they are taking advantage of the government’s EIS scheme, but it does attract international investors too.

“Oxford is a very vibrant eco-system producing exciting technology, and global investors want a front seat here, but they are in the minority,” said Jens.

“I want to encourage more diversity because overseas investors can help young companies open up a global market faster.”

Key sectors attracting investment include artificial intelligence, which touches every area of spin-out activity, along with life sciences, and clean tech (or green tech), because everyone understands the importance of energy transition.

“Angel investors perhaps look at their investments more personally than larger investment houses, and like to put their money where it can have a positive societal impact,” added Jens.

He urges young companies to take advantage of the well-established and sophisticated support network across Oxfordshire’s scientific community.

“The value of the OION network alone is powerful. Our members support young companies through introductions into all sectors, opening doors to further funding, and just as importantly expertise in commercialising the business.”

Jens urges young companies to write their pitch, hone it to the key points, keep it succinct and deploy it at every event they can.

“Regular updates to your investors, or even those who you might want to engage with in the future are also important,” he added.

“Investors like to be kept informed. It’s all about good communication so that when a company needs more money, the investor knows the story.”

Angel investment is fundamental to a successful UK economy, according to Jens.

“The ideas and technologies that are being developed within our universities could have a materially positive impact on the future. But if young companies don’t attract the funding they need to prove the science and set up a business, their ideas could fall by the wayside – or be lost overseas. And that’s something that everyone should want to avoid.”

THEBUSINESSMAGAZINE.CO.UK

21

LIFE SCIENCES SHOWCASE clinical trials. Researchers will also have increased access to the latest equipment and technology.

More funding for clinical trials

Around 20 per cent of the funding will be directed towards sustainable manufacturing initiatives, promoting efficiency and reducing waste and emissions within the pharmaceutical sector.

UK secures £400m investment to boost clinical trials NHS patients will have earlier access to new treatments and the UK will become the home of cutting-edge health research said the government in August when it launched a joint public-private investment programme worth up to £400 million.

It hopes this world-first public-private collaboration will kickstart economic growth and build an NHS fit for the future.

The Voluntary Scheme for Branded Medicine Pricing, Access and Growth (VPAG) Investment Programme will channel significant investment into the UK’s health

and life sciences sector over the next five years.

It says this is the first major public-private collaboration of this scale in the world and will create 18 new clinical trial hubs to fasttrack the development of new medicines.

By streamlining processes, it will ensure that new treatments move swiftly from labs to wards.

The programme will allocate 75 per cent of its investment to expand the UK’s capacity and capability for commercial

The final five per cent will focus on modernising Health Technology Assessment processes to assess the cost and clinical effectiveness of new treatments.

Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry, said: “The life science industry has the potential to deliver so much more for the UK – but to do this we need to fix the NHS, improve patient access to medicines and invest more in our critical science and regulatory infrastructure.

“The investment programme supports the government’s missions to kickstart economic growth and improving the UK’s clinical trials will also help attract further global investment.”

Nearly £50m unlocked for world-leading UK Biobank following industry backing The UK Biobank, which the government says is the world’s most advanced source of data for health research, secured the backing of Amazon Web Services.

investor Ken Griffin, and matched by government to a total of £32 million. This further contribution means almost £50 million backing has now been achieved for UK Biobank.

Amazon will provide around £8 million worth of cloud computing credits to help ensure the biobank has the infrastructure it needs to securely store and handle its unique health data.

Researchers worldwide can apply to access the de-identified and secure data, and are using it to enable medical breakthroughs, from detecting cardiac disease earlier, to developing tests for Alzheimer’s.

UK biobank is helping the life sciences sector transform healthcare for people across the UK and worldwide. It is a database of in-depth genetic, health and lifestyle information from half a million UK volunteers.

De-identified UK Biobank data is already accessible, securely and worldwide, for approved researchers on the UK Biobank Research Analysis platform.

Amazon’s contribution is being matched by a further £8 million in government investment, and forms part of the public, private and philanthropic group set up to keep the worldleading facility at the forefront of medical research.

In October last year a public-philanthropic consortium was set up to ensure UK Biobank’s long-term future, with initial funding donated by former Google CEO Eric Schmidt and billionaire

22

THEBUSINESSMAGAZINE.CO.UK

Minister for Science, Lord Vallance, said: “While the UK is an enviable destination for life sciences research, tackling the profound challenges that diseases like dementia and cancer pose to society, and the economy, is simply too vast a task for any one country to face alone. By giving approved researchers, the world over, access to an unrivalled volume of health data, UK Biobank exemplifies how a collaborative approach to science can make both the UK and the world healthier and more prosperous.”

NOVEMBER 2024 WEST MIDLANDS

Nuneaton

Birmingham

Coventry

Kidderminster

Rugby

Bromsgrove

WORCESTERSHIRE

South East edition:

Leamington Spa

Redditch

Warwick

Droitwich Spa

Oxfordshire & Thames Valley Berkshire & Buckinghamshire Surrey, Kent & Sussex Solent & South Coast

Stratford-upon-Avon

Worcester

WARWICKSHIRE

Malvern

Evesham

Hereford

Banbury

Broadway Tewkesbury

Cherwell

Chipping Norton

South West & West Midlands edition:

Gloucester

FOREST OF DEAN

Bristol & Bath, Gloucestershire, Worcestershire & Hereford, Coventry & Warwickshire, Swindon & North Wiltshire

Quedgeley

Cheltenham

Bicester

COTSWOLDS

GLOUCESTERSHIRE

OXFORDSHIRE

Witney

Stroud

Lydney

Thornbury

Yate

Wantage

WestonSuper-Mare

High Wycombe Amersham M40

Didcot

Swindon

Marlow Maidenhead

Henley-on-Thames

BERKSHIRE

Chippenham

M4

Bath

Thame

Abingdon

Faringdon

Malmesbury

BRISTOL AVON

Aylesbury

Oxford

Cirencester

SOUTH GLOUCESTERSHIRE

BUCKINGHAMSHIRE

Woodstock

Thatcham

Newbury

Slough Windsor

Heathrow

Reading

Wokingham Camberley

WILTSHIRE

Farnborough Basingstoke

Fleet

M3

M5

Bracknell

Biggin Hill Epsom

Woking

Guilford

Farnham

Ashtead

SURREY

Leatherhead Redhill M23 Gatwick

A3

Glastonbury

A303

SOMERSET

Canterbury

KENT Dover

Ashford

Royal Tunbridge Wells

Folkestone

Crawley Winchester

Taunton

HAMPSHIRE WEST & EAST SUSSEX

Yeovil Southampton New Forest

M27

DEVON A30

Havant Portsmouth

DORSET Exeter

Maidstone

Horsham

Salisbury

Tiverton

A30

Chatham

M25

Hastings Chichester

A27

Brighton Eastbourne

Poole

A35

Bournemouth

ISLE OF WIGHT

Launceston Weymouth

Torquay Newquay

CORNWALL

A38

Plymouth

St Austell A30

Truro

Editorial

St Ives Falmouth Penzance

Print Editor

Nicky Godding nicky.godding@thebusinessmagazine.co.uk

Senior Reporter

Championing Regional Business

Daniel Face daniel.face@thebusinessmagazine.co.uk

The region’s most influential B2B magazine, in print and online for news, features, interviews and business sector analysis.

Research & Rankings Researcher

Laura Clarke laura.clarke@thebusinessmagazine.co.uk

Events

2025 Print issues will be published in January, March, May, July, September and November

Events Executive

Lauren McCarron lauren.mccarron@thebusinessmagazine.co.uk

Events Assistant

Katie Jackson katie.jackson@thebusinessmagazine.co.uk

NEXT ISSUE: JANUARY 2025

Marketing Digital Marketing

Scott Whittle scott.whittle@thebusinessmagazine.co.uk

Commercial

Contact us Managing Director

Richard Thompson richard.thompson@thebusinessmagazine.co.uk

Managing Editor

Stephen Emerson stephen.emerson@thebusinessmagazine.co.uk

Operations Director

Jo Whittle jo.whittle@thebusinessmagazine.co.uk

Visit our magazine online thebusinessmagazine.co.uk Follow us: @TheBusinessMag linkedin.com/company/the-business-magazine

Head of Client Relations Thames Valley

Peter Laurie

Business Manager South Coast

Alan Lindstrom

Business Development Manager South West & West Midlands

Owen Thomas

Production Manager

Steve Banbury

peter.laurie@thebusinessmagazine.co.uk alan.lindstrom@thebusinessmagazine.co.uk owen.thomas@thebusinessmagazine.co.uk

steve.banbury@thebusinessmagazine.co.uk

Events

events@thebusinessmagazine.co.uk

Accounts

finance@thebusinessmagazine.co.uk

General Enquiries

editorial@thebusinessmagazine.co.uk

Magazine Design: Origin Creative I www.origin-creative.com

Publisher: The Business Magazine Group Ltd – Company number 13202910

Magazine Printers: The Manson Group I www.mansongroup.co.uk

Registered Office: 24 Bell lane, Blackwater, Camberley, Surrey, GU17 0NW

The Business Magazine is published by The Business Magazine Group Ltd. Our readers are business owners, senior executives, directors, key influencers, entrepreneurs, innovators, and those working in further and higher education and government departments and business support organisations. Any opinions expressed by those quoted in this magazine are their own and do not necessarily represent or reflect those of The Business Magazine Group Ltd. No part of this publication may be reproduced or used in any form of advertising or promotion without the express written permission of the Managing Director, Managing Editor, or Print Editor.

ISSN 2516 – 0389 (Print) ISSN 2753 – 4561 (Online)